Page 118 - CL Armchair Case

October, New York Attorney General antitrust bureau
investigating Turing: company might be 'unlawfully'

restraining competition.

November, Turing said it would cut the price of Daraprim by

up to 50% for some patients.

November, Shkreli’s investor group made a 1.2 million share

purchase for a 70% stake in KaloBios Pharmaceuticals Inc.

Shkreli appointed as both CEO and Chairman of KalBios.

th
December 16 Shkreli arrested and charged with securities
fraud and conspiracy and released on a $5 million bond.
KaloBios remove him from the board.

December 17 Shkreli resigns from Turing.

December 29, KaloBios filed for Chapter 11 bankruptcy.

2016 January Shkreli retained criminal defense attorney Benjamin
Brafman

Shkreli subpoenaed to appear before the Committee on
Oversight and Government Reform of the U.S. House of
Representatives

February 4 Shkreli appeared before the House committee

June Shkreli trial date set for 26 June 2017